E. Ohman J or Asset Management AB Lowers Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

E. Ohman J or Asset Management AB decreased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,250 shares of the medical equipment provider’s stock after selling 900 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Zimmer Biomet were worth $1,047,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Lmcg Investments LLC boosted its stake in shares of Zimmer Biomet by 9.5% in the first quarter. Lmcg Investments LLC now owns 61,260 shares of the medical equipment provider’s stock worth $6,933,000 after buying an additional 5,311 shares during the last quarter. Gilman Hill Asset Management LLC boosted its position in Zimmer Biomet by 3.9% during the first quarter. Gilman Hill Asset Management LLC now owns 29,120 shares of the medical equipment provider’s stock worth $3,296,000 after purchasing an additional 1,081 shares in the last quarter. Bridge Creek Capital Management LLC boosted its position in Zimmer Biomet by 0.8% during the first quarter. Bridge Creek Capital Management LLC now owns 26,836 shares of the medical equipment provider’s stock worth $3,037,000 after purchasing an additional 215 shares in the last quarter. ST Germain D J Co. Inc. boosted its position in Zimmer Biomet by 12.4% during the first quarter. ST Germain D J Co. Inc. now owns 102,072 shares of the medical equipment provider’s stock worth $11,553,000 after purchasing an additional 11,227 shares in the last quarter. Finally, Paladin Wealth LLC boosted its position in Zimmer Biomet by 6.8% during the first quarter. Paladin Wealth LLC now owns 5,829 shares of the medical equipment provider’s stock worth $660,000 after purchasing an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $92.47 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The stock has a market cap of $18.30 billion, a PE ratio of 20.78, a P/E/G ratio of 1.95 and a beta of 0.72. The stock has a 50 day moving average price of $97.95 and a 200 day moving average price of $104.14.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.89 billion. During the same quarter last year, the firm earned $1.94 earnings per share. The business’s revenue for the quarter was up 1.1% on a year-over-year basis. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 1.04%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.24%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZBH. Truist Financial set a $101.00 price target on Zimmer Biomet in a research report on Tuesday, May 6th. The Goldman Sachs Group lowered their price target on Zimmer Biomet from $120.00 to $104.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 6th. Royal Bank of Canada lowered their price target on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. BTIG Research restated a “buy” rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Finally, Raymond James decreased their target price on Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $111.53.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.